CytomX Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders: Elaine V. Jones, Ph.D.

CytomX Therapeutics, Inc.’s own tally for this item (“Elect Director: Elaine V. Jones Ph.D.”): 131,377,301 for, 17,428,951 against, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 26 asset managers below reported 46,592,208 for, 861,340 against.

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

Description as filed by funds: To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders: Matthew P. Young

CytomX Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew P. Young”): 146,742,827 for, 2,062,471 against, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 26 asset managers below reported 46,967,912 for, 485,636 against.

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

Description as filed by funds: To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares;

CytomX Therapeutics, Inc.’s own tally for this item (“3. An amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares”): 178,362,995 for, 4,771,689 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 26 asset managers below reported 47,430,699 for, 22,848 against.

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

Description as filed by funds: To approve an amendment to our Amended and Restated Employee Stock Purchase Plan;

CytomX Therapeutics, Inc.’s own tally for this item (“5. An amendment to the Company's Amended and Restated Employee Stock Purchase Plan, as described in the Proxy Statement”): 147,375,197 for, 1,468,576 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the Company's Amended and Restated Employee Stock Purchase Plan, as described in the Proxy Statement.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of CytomX Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 25 managers: 47,453,545 for, 4 against.

Institutional-manager reports, all 1 managers: 2,246,840 for.

The 25 asset managers below reported 47,368,492 for, 55,973 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and

CytomX Therapeutics, Inc.’s own tally for this item (“6. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC”): 147,127,715 for, 1,722,679 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 25 managers: 47,453,543 for, 5 against.

Institutional-manager reports, all 96 managers: 105,309,424 for, 488,353 against, 27,192 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO HOLD A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES BY STOCKHOLDERS ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 24 managers: 1 abstained, 46,940,498 1 year, 483,557 3 year, 411 unknown.

Institutional-manager reports, all 91 managers: 7,229,055 for, 79,450,363 1 year, 767,482 3 year, 457,717 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026;

CytomX Therapeutics, Inc.’s own tally for this item (“2. The selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026”): 182,976,052 for, 382,681 against — passed, per its Form 8-K filed June 22, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 26 asset managers below reported 47,453,380 for, 169 against.

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.